Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2003 Mar;58(3):211–216. doi: 10.1136/thorax.58.3.211

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

D Price 1, D Hernandez 1, P Magyar 1, J Fiterman 1, K Beeh 1, I James 1, S Konstantopoulos 1, R Rojas 1, J A van Noord 1, M Pons 1, L Gilles 1, J Leff 1
PMCID: PMC1746596  PMID: 12612295

Abstract

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma.

Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n=448) or budesonide 1600 µg/day (n=441) for 12 weeks.

Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1–3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonide group (20.1 v 9.6 l/min, p<0.001), indicating faster onset of action in the montelukast group. Both groups showed similar improvements with respect to "as needed" ß agonist use, mean daytime symptom score, nocturnal awakenings, exacerbations, asthma free days, peripheral eosinophil counts, and asthma specific quality of life. Both montelukast + budesonide and double dose budesonide were generally well tolerated.

Conclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonide in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.

Full Text

The Full Text of this article is available as a PDF (217.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bisgaard H., Loland L., Oj J. A. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med. 1999 Oct;160(4):1227–1231. doi: 10.1164/ajrccm.160.4.9903004. [DOI] [PubMed] [Google Scholar]
  2. Boe J., Rosenhall L., Alton M., Carlsson L. G., Carlsson U., Hermansson B. A., Hetta L., Kiviloog J., Karlson B. W., Lundbäck B. Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy. 1989 Jul;44(5):349–355. doi: 10.1111/j.1398-9995.1989.tb00457.x. [DOI] [PubMed] [Google Scholar]
  3. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  4. Hanania N. A., Chapman K. R., Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995 Feb;98(2):196–208. doi: 10.1016/S0002-9343(99)80404-5. [DOI] [PubMed] [Google Scholar]
  5. Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001 Aug 4;323(7307):253–256. doi: 10.1136/bmj.323.7307.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Israel E., Banerjee T. R., Fitzmaurice G. M., Kotlov T. V., LaHive K., LeBoff M. S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001 Sep 27;345(13):941–947. doi: 10.1056/NEJMoa002304. [DOI] [PubMed] [Google Scholar]
  7. Johansson S. A., Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. Allergy. 1988 Apr;43(3):173–178. doi: 10.1111/j.1398-9995.1988.tb00415.x. [DOI] [PubMed] [Google Scholar]
  8. Juniper E. F., Guyatt G. H., Epstein R. S., Ferrie P. J., Jaeschke R., Hiller T. K. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992 Feb;47(2):76–83. doi: 10.1136/thx.47.2.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Juniper E. F., Guyatt G. H., Willan A., Griffith L. E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994 Jan;47(1):81–87. doi: 10.1016/0895-4356(94)90036-1. [DOI] [PubMed] [Google Scholar]
  10. Knorr B., Matz J., Bernstein J. A., Nguyen H., Seidenberg B. C., Reiss T. F., Becker A. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998 Apr 15;279(15):1181–1186. doi: 10.1001/jama.279.15.1181. [DOI] [PubMed] [Google Scholar]
  11. Laviolette M., Malmstrom K., Lu S., Chervinsky P., Pujet J. C., Peszek I., Zhang J., Reiss T. F. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999 Dec;160(6):1862–1868. doi: 10.1164/ajrccm.160.6.9803042. [DOI] [PubMed] [Google Scholar]
  12. Löfdahl C. G., Reiss T. F., Leff J. A., Israel E., Noonan M. J., Finn A. F., Seidenberg B. C., Capizzi T., Kundu S., Godard P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999 Jul 10;319(7202):87–90. doi: 10.1136/bmj.319.7202.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Piñeiro A., Wei L. X., Seidenberg B. C., Reiss T. F. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999 Mar 16;130(6):487–495. doi: 10.7326/0003-4819-130-6-199903160-00005. [DOI] [PubMed] [Google Scholar]
  14. Pauwels R. A., Löfdahl C. G., Postma D. S., Tattersfield A. E., O'Byrne P., Barnes P. J., Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. doi: 10.1056/NEJM199711133372001. [DOI] [PubMed] [Google Scholar]
  15. Pizzichini E., Leff J. A., Reiss T. F., Hendeles L., Boulet L. P., Wei L. X., Efthimiadis A. E., Zhang J., Hargreave F. E. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 1999 Jul;14(1):12–18. doi: 10.1034/j.1399-3003.1999.14a04.x. [DOI] [PubMed] [Google Scholar]
  16. Reddel H. K., Jenkins C. R., Marks G. B., Ware S. I., Xuan W., Salome C. M., Badcock C. A., Woolcock A. J. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J. 2000 Aug;16(2):226–235. doi: 10.1034/j.1399-3003.2000.16b08.x. [DOI] [PubMed] [Google Scholar]
  17. Reiss T. F., Chervinsky P., Dockhorn R. J., Shingo S., Seidenberg B., Edwards T. B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998 Jun 8;158(11):1213–1220. doi: 10.1001/archinte.158.11.1213. [DOI] [PubMed] [Google Scholar]
  18. Santanello N. C., Barber B. L., Reiss T. F., Friedman B. S., Juniper E. F., Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J. 1997 Mar;10(3):646–651. [PubMed] [Google Scholar]
  19. Simons F. E., Villa J. R., Lee B. W., Teper A. M., Lyttle B., Aristizabal G., Laessig W., Schuster A., Perez-Frias J., Sekerel B. E. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001 May;138(5):694–698. doi: 10.1067/mpd.2001.112899. [DOI] [PubMed] [Google Scholar]
  20. Sont J. K., Willems L. N., Bel E. H., van Krieken J. H., Vandenbroucke J. P., Sterk P. J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1043–1051. doi: 10.1164/ajrccm.159.4.9806052. [DOI] [PubMed] [Google Scholar]
  21. Storms W., Michele T. M., Knorr B., Noonan G., Shapiro G., Zhang J., Shingo S., Reiss T. F. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy. 2001 Jan;31(1):77–87. doi: 10.1046/j.1365-2222.2001.00969.x. [DOI] [PubMed] [Google Scholar]
  22. Virchow J. C., Jr, Prasse A., Naya I., Summerton L., Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):578–585. doi: 10.1164/ajrccm.162.2.9905041. [DOI] [PubMed] [Google Scholar]
  23. Ward C., Pais M., Bish R., Reid D., Feltis B., Johns D., Walters E. H. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002 Apr;57(4):309–316. doi: 10.1136/thorax.57.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Woolcock A., Lundback B., Ringdal N., Jacques L. A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. doi: 10.1164/ajrccm.153.5.8630590. [DOI] [PubMed] [Google Scholar]
  25. van Noord J. A., Schreurs A. J., Mol S. J., Mulder P. G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999 Mar;54(3):207–212. doi: 10.1136/thx.54.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES